300813.SZ
泰林生物
SZSE · Healthcare · C 制造业 · CN
CNY 20.37
−3.60%Year over year
Reported trailing growth
- Revenue
- +2.0%
- EBITDA
- —
- EBIT
- +72.2%
- EPS
- +54.8%
- Free cash flow
- -97.5%
- Operating cash flow
- +171.6%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- -3.2%
- EBITDA
- -25.6%
- EBIT
- -40.3%
- Net income
- -40.9%
- EPS
- -42.6%
- Free cash flow
- -76.0%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026